Lesinurad: First Global Approval

FRI0333 Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 2)

(2015) T. Bardin et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0307 Lesinurad Monotherapy in Gout Patients Intolerant to Xanthine Oxidase Inhibitors (Light): A Randomized, Double-Blind, Placebo-Controlled, 6-Month Phase III Clinical Trial

(2015) A.-K. Tausche et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0313 Relationship Between Sustained Lowering of Serum Urate Levels and Improvements in Gout Flares and Tophus Area: Pooled Exploratory Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitor Combination Therapy

(2015) R. Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

AB1064 No clinically meaningful drug interactions expected between lesinurad, a novel oral uricosuric agent, and drugs most commonly used by gout patients

(2014) L.-T. Yeh et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study

(2014) F. Perez-Ruiz et al.   ANNALS OF THE RHEUMATIC DISEASES

Gout

(2013) E. Roddy et al.   BMJ-British Medical Journal

Gout therapeutics: new drugs for an old disease

(2010) Christopher M Burns et al.   LANCET